title: Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumor.
abstract: Calcium phosphate (CaP) nanoparticles (NP) with an asymmetric lipid bilayer coating have been designed for targeted delivery of siRNA to the tumor. An anionic lipid, dioleoylphosphatydic acid (DOPA), was employed as the inner leaflet lipid to coat the nano-size CaP cores, which entrap the siRNA, such that the coated cores were soluble in organic solvent. A suitable neutral or cationic lipid was used as the outer leaflet lipid to form an asymmetric lipid bilayer structure verified by the measurement of NP zeta potential. The resulting NP was named LCP-II with a size of about 25 to 30nm in diameter and contained a hollow core as revealed by TEM imaging. PEGylation of NP was done by including a PEG-phospholipid conjugate, with or without a targeting ligand anisamide, in the outer leaflet lipid mixture. The sub-cellular distribution studied in the sigma receptor positive human H460 lung cancer cells indicated that LCP-II could release more cargo to the cytoplasm than our previous lipid/protamine/DNA (LPD) formulation, leading to a significant (~40 fold in vitro and ~4 fold in vivo) improvement in siRNA delivery. Bio-distribution study showed that LCP-II required more PEGylation for MPS evasion than the previous LPD, probably due to increased surface curvature in LCP-II.
authors: Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
authors: Jun
authors: J
authors: Li
authors: Yang
authors: Y
authors: Yang
authors: Leaf
authors: L
authors: Huang
mesh_terms: D000818:Animals; D002130:Calcium Phosphates / Q000008:administration & dosage* / Q000737:chemistry; D045744:Cell Line, Tumor; D005229:Fatty Acids, Monounsaturated / Q000008:administration & dosage / Q000737:chemistry; D005260:Female; D020868:Gene Silencing; D018014:Gene Transfer Techniques; D006801:Humans; D008051:Lipid Bilayers / Q000008:administration & dosage* / Q000737:chemistry; D051379:Mice; D008819:Mice, Nude; D053758:Nanoparticles / Q000008:administration & dosage* / Q000737:chemistry; D009369:Neoplasms / Q000235:genetics* / Q000378:metabolism; D010712:Phosphatidic Acids / Q000008:administration & dosage / Q000737:chemistry; D010713:Phosphatidylcholines / Q000008:administration & dosage / Q000737:chemistry; D000644:Quaternary Ammonium Compounds / Q000008:administration & dosage / Q000737:chemistry; D034741:RNA, Small Interfering / Q000008:administration & dosage* / Q000737:chemistry
chemical_list: D002130:Calcium Phosphates; D005229:Fatty Acids, Monounsaturated; D008051:Lipid Bilayers; D010712:Phosphatidic Acids; D010713:Phosphatidylcholines; D000644:Quaternary Ammonium Compounds; D034741:RNA, Small Interfering; C037657:dioleoylphosphatidic acid; C020243:calcium phosphate; C017251:1,2-oleoylphosphatidylcholine; C070046:1,2-dioleoyloxy-3-(trimethylammonium)propane